Acura Pharmaceuticals, Inc. ACUR

Company Overview

Acura Pharmaceuticals, Inc. (formerly known as Fleming Pharmaceuticals) is a specialty pharmaceutical company focused on the development of abuse-deterrent and misuse-resistant drug technologies, primarily for opioid and over-the-counter medication products. The company has historically operated within the prescription pharmaceutical and drug delivery technology industries, with a business model centered on intellectual property licensing, formulation development, and commercialization partnerships. Public disclosures in SEC filings indicate that Acura’s primary strategic emphasis has been on its proprietary abuse-deterrence platforms, including technologies intended to reduce oral, nasal, and injectable misuse of opioid products.

The company’s principal business lines have included the development of opioid analgesic formulations using its proprietary technologies, most notably the AVERSION platform. Acura previously commercialized products through collaboration arrangements, including relationships with larger pharmaceutical manufacturers and distributors. Over time, the company evolved from a traditional pharmaceutical manufacturer into a development-stage specialty pharmaceutical business focused on intellectual property and formulation science. Publicly available filings also indicate periods of financial distress, operational reductions, and uncertainty regarding long-term commercialization activity.